MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.800
+0.080
+2.94%
After Hours: 2.850 +0.05 +1.79% 17:05 05/26 EDT
OPEN
2.730
PREV CLOSE
2.720
HIGH
2.850
LOW
2.700
VOLUME
135.36K
TURNOVER
0
52 WEEK HIGH
5.44
52 WEEK LOW
2.020
MARKET CAP
239.15M
P/E (TTM)
-1.2273
1D
5D
1M
3M
1Y
5Y
Immutep to Present at Investor Conferences
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep...
GlobeNewswire · 6d ago
Immutep Appoints Leading Oncologists to its Clinical Advisory Board
SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today t...
GlobeNewswire · 05/18 12:00
Bright Health, TransMedics top healthcare gainers; Connect Biopharma, Amarin lead losers' pack
Gainers: Bright Health Group (BHG) +21%. TransMedics Group (TMDX) +21%. Belite Bio (BLTE) +11%. Sharps Technology (STSS) +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma (CNTB) -45%. Amarin (AMRN) -43%. Kezar Life Sciences (KZR) -35%. MacroGenics (MGNX)...
Seekingalpha · 05/04 14:04
Immutep Presents New and Significant Data from the AIPAC Study
Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the efti group, but not in the placebo groupThe increase in ph...
GlobeNewswire · 05/04 12:00
Immutep Announced Statistically Significant Data From AIPAC Study
– Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis data from its P...
Benzinga · 05/04 09:19
Top Premarket Gainers
MT Newswires · 05/04 08:03
Immutep Quarterly Activities Report
New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmarkConstructive feedback from the US FDA regarding the clinical development prog...
GlobeNewswire · 04/29 12:00
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new in...
GlobeNewswire · 04/28 12:00
More
No Data
Learn about the latest financial forecast of IMMP. Analyze the recent business situations of Immutep through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMMP stock price target is 8.55 with a high estimate of 9.13 and a low estimate of 8.11.
High9.13
Average8.55
Low8.11
Current 2.800
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Q1 2021
Q2 2021
Institutional Holdings
Institutions: 28
Institutional Holdings: 5.70M
% Owned: 6.68%
Shares Outstanding: 85.41M
TypeInstitutionsShares
Increased
8
242.90K
New
2
41.07K
Decreased
6
138.14K
Sold Out
3
28.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman/Independent Director
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Secretary
Indira Naidu
Non-Executive Director
Lucy Turnbull
No Data
No Data
About IMMP
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.